Great Basin Scientific Inc. (Nasdaq: GBSN)
initiated a clinical trial for its Bordatella Direct Test to detect the
Bordatella pertussis bacterium. The stock price leaped $1.00 to $2.73.
Great Basin Scientific initiates clinical trial
May 18, 2016 at 12:16 PM EDT